Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma has requested an immediate trading halt on its securities on the ASX while it analyses interim pharmacokinetic data from the pivotal phase II clinical trial of its SPONTAN Nasal Spray for erectile dysfunction. Trading in the company’s shares will remain halted until either the interim clinical results are released to the market or normal trading commences on Friday, 1 May 2026, with the company stating it is unaware of any reason the halt should not be granted and signalling potentially market-sensitive trial outcomes for investors.
More about LTR Pharma Limited
LTR Pharma Limited is an Australian biopharmaceutical company listed on the ASX that is developing SPONTAN Nasal Spray, a treatment for erectile dysfunction. The company is focused on advancing this product through clinical trials, positioning itself within the sexual health and urology therapeutics market.
Average Trading Volume: 188,861
Technical Sentiment Signal: Sell
Current Market Cap: A$70.89M
For detailed information about LTP stock, go to TipRanks’ Stock Analysis page.